AWM Investment Company Inc. Buys New Shares in Avadel Pharmaceuticals PLC. $AVDL

Key Points

• AWM Investment Company Inc. has acquired 41,000 shares of Avadel Pharmaceuticals PLC, valued at approximately $321,000, as detailed in its recent SEC filing.
• Numerous other hedge funds have increased their holdings in Avadel, with Two Seas Capital LP significantly boosting its stake by over 90% in the last quarter.
• Avadel's recent quarterly earnings beat analyst expectations, reporting $0.10 earnings per share and $68.13 million in revenue, marking a substantial 64.1% year-over-year increase.

AWM Investment Company Inc. bought a new stake in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 41,000 shares of the company's stock, valued at approximately $321,000.

A number of other institutional investors have also modified their holdings of the stock. Janus Henderson Group PLC increased its holdings in shares of Avadel Pharmaceuticals by 5.7% in the fourth quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company's stock valued at $148,117,000 after purchasing an additional 753,332 shares during the period. Two Seas Capital LP increased its holdings in shares of Avadel Pharmaceuticals by 90.6% in the fourth quarter. Two Seas Capital LP now owns 4,296,449 shares of the company's stock valued at $45,156,000 after purchasing an additional 2,042,669 shares during the period. Braidwell LP increased its holdings in shares of Avadel Pharmaceuticals by 21.2% in the fourth quarter. Braidwell LP now owns 4,105,726 shares of the company's stock valued at $43,151,000 after purchasing an additional 716,787 shares during the period. Wealth Effects LLC increased its holdings in shares of Avadel Pharmaceuticals by 1.1% in the first quarter. Wealth Effects LLC now owns 2,369,122 shares of the company's stock valued at $18,550,000 after purchasing an additional 24,992 shares during the period. Finally, Tang Capital Management LLC grew its holdings in Avadel Pharmaceuticals by 21.7% during the fourth quarter. Tang Capital Management LLC now owns 1,497,500 shares of the company's stock worth $15,739,000 after acquiring an additional 267,500 shares during the period. Institutional investors and hedge funds own 69.19% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on AVDL. Wall Street Zen raised Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Lifesci Capital raised Avadel Pharmaceuticals to a "strong-buy" rating in a report on Wednesday. Zacks Research raised Avadel Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 8th. Finally, UBS Group upped their price objective on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $20.86.

Avadel Pharmaceuticals Trading Up 5.1%

Shares of NASDAQ:AVDL traded up $0.77 on Friday, hitting $15.76. The company had a trading volume of 2,024,679 shares, compared to its average volume of 1,284,834. Avadel Pharmaceuticals PLC. has a 52-week low of $6.38 and a 52-week high of $16.66. The business has a 50 day moving average of $12.00 and a 200 day moving average of $9.75. The company has a market cap of $1.53 billion, a PE ratio of -525.33 and a beta of 1.58.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.08. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The business had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. During the same period in the prior year, the business earned ($0.14) earnings per share. The business's revenue was up 64.1% on a year-over-year basis. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Avadel Pharmaceuticals PLC. will post -0.51 EPS for the current year.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.